Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer


Acquired | Acquired

About INIM Pharma

INIM Pharma AB is a Swedish drug development company focusing on the development of immunomodulatory drugs for interstitial lung diseases.

INIM Pharma Headquarter Location

Engelbrektsplan 1

Stockholm, 114 34,


Latest INIM Pharma News

Vicore Pharma Holding AB VICOSE Funded through 2021E beyond key inflection points

Dec 13, 2018

KEY TAKEAWAY Vicore has had a busy few months during which it acquired INIM Pharma and raised SEK242m (c.EUR23m) through a rights issue (SEK82.4m) and a directed share issue (SEK160m), which extended the company's cash runway to YE2021E. By this time Vicore should have reached key inflection points for its two lead assets: Phase IIa proof-of-concept for VP01 (C21) in idiopathic pulmonary fibrosis ("IPF") and Phase I for reformulated immunomodulatory imide drug ("IMiD") VP02 in IPF cough. We expect VP02 to be launched in 2025E, up to one year earlier than VP01, due to its shorter development programme (fewer, smaller and shorter trials). We have updated our models and valuation to include both fundraises, VP02 sales, a delay to the expected launch of VP01, and Vicore's revised strategy to commercialise both assets on its own. Our valuation remains broadly unchanged at SEK42 per share (>130% upside). We maintain our OUTPERFORM recommendation. Reformulated IMiD (VP02) for local lung delivery adds SEK9 / share to valuation VP02 is a novel formulation of one of the four marketed IMiDs. It is being developed for IPF cough, the most debilitating symptom associated with the disease affecting c.80% of patients and for which there is currently no approved treatment. The rationale is that first-generation IMiD thalidomide demonstrated a significant, clinically relevant effect on alleviating IPF cough in a 24-patient trial. Vicore plans to conduct an abbreviated development programme. A short Phase I trial due to start in Q1/2020E is expected to be followed by a Phase II trial in Q4/2020E, after which VP02 may enter a registrational Phase II/III trial in H2/2022E. We model approval in the US and Europe in 2025E and peak sales of >$720m by 2038E. VP01 launch delayed to 2026E due to Phase I extension New CEO Carl-Johan Dalsgaard conducted a strategic review that resulted in two key changes to the VP01 programme: (1) Extension of Phase I to identify the maximum tolerated dose ("MTD"), and (2) a longer and larger Phase IIa PoC trial to achieve a meaningful functional readout. This has led us to push back the expected launch to 2026E. We also now model that Vicore commercialises VP01 on its own (vs. a licensing deal previously) as this is management's preferred approach. We continue to believe that the molecule's profile should allow it to capture at least 15% of the market and generate peak sales of c.$1.5bn. SoTP valuation broadly unchanged at SEK42 per share Based on our estimates, VP01 remains Vicore's most valuable asset, accounting for nearly 70% of our valuation. VP02 accounts for approx. 20% despite the faster path to market and lower development costs, due to lower peak sales expectations compared to VP01 ($732m vs. c.$1.5bn) and a higher risk adjustment (90% vs. 85%). Kind regards, Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel. goetzpartners securities Limited - Team Members Equity Research Analysts - Martin Brunninger, Brigitte de Lima, Chris Redhead and Martin Piehlmeier. Sales / Marketing - Erland Sternby. Corporate Access and IR - Tanya Tracey and Bettina Ellinghorst. Compliance - Paul W. Dunne. GPSL has a formal client relationship with Vicore Pharma Holding AB. GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5). In accordance with the General Data Protection Regulation (" GDPR ") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail: About GPSL : goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients. This communication (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this communication in error or are not the intended recipient of this communication, please delete and destroy all copies in your possession, notify the sender that you have received this communication, and note that any review or dissemination of, or the taking of any action in reliance on this communication is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this communication nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this communication has been maintained nor that this communication is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563). GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaMetry , AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, ResearchFN , Research Tree , RNS Reach, Sentieo and Thomson Reuters. Please copy the below link and paste it into your browser for the full pdf version of the equity research report:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.